Artivio’s On-X Aortic Valve shows safety in real world data

Artivion presented data from its On-X Aortic Heart Valve Low INR post-market study presented at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting in Vienna. Real world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin. Results show a significantly lower composite primary endpoint of thromboembolism, valve thrombosis, and major bleeding of 2.31% compared to the pre-defined historic control rate of 5.39%, pless than0.0001, driven by an 85% reduction in major bleeding and a 73% reduction in all bleeding. The data reflected an improvement in outcomes compared to the On-X Aortic Low INR IDE Study data first published in 2014.